Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 1–12 of 208 trials
RecruitingATTR (transthyretin)
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting (opens on ClinicalTrials.gov)
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran…
- Study
- Observational (registry, imaging)
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: GermanyJapanUnited States
NCT07358078Updated 9 October 2026
RecruitingNot specified
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (opens on ClinicalTrials.gov)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
Recruiting in: JapanSouth KoreaTaiwanUnited States
NCT07589595Updated 8 October 2026
RecruitingATTR (transthyretin)
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting (opens on ClinicalTrials.gov)
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in…
- Study
- Observational (registry, imaging)
- Sponsor
- Bayer
Recruiting in: AustriaBelgiumCroatiaDenmark+13
NCT07235462Updated 8 October 2026
RecruitingNot specified
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability…
- Study
- Interventional (treatment)
- Sponsor
- University Hospital, Montpellier
Recruiting in: France
NCT07494942Updated 8 October 2026
RecruitingATTR (transthyretin)
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program (opens on ClinicalTrials.gov)
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
- Study
- Observational (registry, imaging)
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: FranceGermanyItalyNetherlands+3
NCT05040373Updated 8 October 2026
RecruitingATTR (transthyretin)
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (opens on ClinicalTrials.gov)
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Alnylam Pharmaceuticals
Recruiting in: ArgentinaAustraliaBrazilCanada+18
NCT07223203Updated 8 October 2026
RecruitingAL (light chain)
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial (opens on ClinicalTrials.gov)
This phase II trial compares shorter-duration versus longer-duration maintenance therapy with daratumumab for improving survival in patients who have received initial treatment with daratumumab…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Mayo Clinic
Recruiting in: United States
NCT05898646Updated 1 October 2026
RecruitingCerebral amyloid angiopathy
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy (opens on ClinicalTrials.gov)
Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Beijing Tiantan Hospital
Recruiting in: China
NCT07250035Updated 30 September 2026
RecruitingAL (light chain)
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders (opens on ClinicalTrials.gov)
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM)…
- Study
- Observational (registry, imaging)
- Sponsor
- Mayo Clinic
Recruiting in: United States
NCT07850284Updated 30 September 2026
RecruitingNot specified
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (opens on ClinicalTrials.gov)
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Mayo Clinic
Recruiting in: United States
NCT07285044Updated 30 September 2026
RecruitingAL (light chain)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (opens on ClinicalTrials.gov)
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
Recruiting in: BelgiumFranceJapanNetherlands+3
NCT05652335Updated 28 September 2026
RecruitingAL (light chain)
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma (opens on ClinicalTrials.gov)
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
Recruiting in: AustraliaIsraelNetherlandsSpain+1
NCT06768489Updated 25 September 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 9 October 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.